| Next 10 |
Ad
CBAY News and Press CymaBay Therapeutics Inc.
-
Redefining Expectations for PBC Patients September 22, 2022 at 10:30 AM ET NEWARK, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic d...
-
NEWARK, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the H.C. Wa...
-
NEWARK, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in a mini sympo...
-
Image source: The Motley Fool. CymaBay Therapeutics Inc. (NASDAQ: CBAY) Q2 2022 Earnings Call Aug 11, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: CymaBay Therapeutics Inc. (CBAY) Q2 2022 Earnings Call Transcript...
-
Cymabay Therapeutics, Inc. (CBAY) Q2 2022 Earnings Conference Call August 11, 2022, 16:30 ET Company Participants Paul Quinlan - General Counsel, Chief Compliance Officer & Corporate Secretary Sujal Shah - President, CEO & Director Charles McWherter - SVP...
-
CymaBay Therapeutics press release ( NASDAQ: CBAY ): Q2 GAAP EPS of -$0.31 misses by $0.01 . Shares +5% . Held $170.8 million in cash, cash equivalents and investments as of June 30, 2022. We believe that cash and investments on hand are sufficient to fund Cyma...
-
Enrollment completed in RESPONSE with 193 patients enrolled in over 20 countries Conference call and webcast today at 4:30 p.m. ET NEWARK, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focuse...
-
CymaBay Therapeutics to Report Second Quarter of 2022 Financial Results on Thursday, August 11, 2022
NEWARK, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live aud...
-
NEWARK, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the completion of enrollment for RESPONSE, a glo...
-
Results from the phase 3 RESPONSE study, which is using Seladelpar for the treatment of patients with primary biliary Cholangitis, are expected in 2023. PBC patients treated with Seladelpar over a 2-year period saw a decrease in GLOBE PBC Score and improved transplant-free survival. ...
Stock Information
CymaBay Therapeutics Inc. Company Name:
CBAY Stock Symbol:
NASDAQ Market:
CymaBay Therapeutics Inc. Website:
MENU
CBAY
CBAY Quote
CBAY Short
CBAY News
CBAY Articles
Get CBAY Alerts
News, Short Squeeze, Breakout and More Instantly...
Ad
-
Redefining Expectations for PBC Patients September 22, 2022 at 10:30 AM ET NEWARK, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic d...
-
NEWARK, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the H.C. Wa...
-
NEWARK, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in a mini sympo...